8-K: Entera Bio Secures FDA Agreement on BMD as Primary Endpoint for Pivotal EB613 Osteoporosis Study

Entera Bio announced FDA agreement to use Bone Mineral Density (BMD) as the primary endpoint for its pivotal Phase 3 study of EB613, an oral treatment for post-menopausal osteoporosis, marking a significant regulatory shift.

Summary

• The U.S. Food and Drug Administration (FDA) agreed with Entera Bio's proposal to use change in total hip Bone Mineral Density (BMD) as the primary endpoint for the New Drug Application (NDA) filing for EB613.
• The EB613 NDA will be supported by a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study in women with postmenopausal osteoporosis.
• Incidence of new or worsening vertebral fractures will be evaluated as the key secondary endpoint in the Phase 3 study.
• This agreement represents a shift from precedent, as previous placebo-controlled Phase 3 studies for new osteoporosis drugs typically required incidence of fracture as the primary endpoint.
• The regulatory update is considered a major milestone, allowing Entera Bio to advance its clinical development program without waiting for the FDA's qualification of the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE).
• On June 12, 2025, Entera received FDA agreement that comprehensive nonclinical developmental and reproductive toxicity (DART) studies are not required for EB613.
• On May 14, 2025, Entera received FDA concurrence that dedicated oral carcinogenicity studies are not warranted for EB613.
• EB613 is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis, aiming to address a significant unmet medical need where over 200 million women globally are estimated to have osteoporosis and remain vastly undertreated.

Sentiment

Score: 9

Explanation: The FDA's agreement on BMD as a primary endpoint for the pivotal Phase 3 study is a highly significant positive development for Entera Bio. This regulatory flexibility substantially de-risks the development pathway for EB613, potentially accelerating time to market and reducing trial costs. This milestone, combined with prior waivers for DART and carcinogenicity studies, positions the company favorably in a market with high unmet medical need.

Positives

• FDA agreement on Bone Mineral Density (BMD) as the primary endpoint for the pivotal Phase 3 study of EB613, potentially accelerating the development timeline and reducing study costs compared to fracture endpoint studies.
• The FDA's decision allows advancement of the clinical program without waiting for the SABRE initiative's qualification, streamlining the regulatory path.
• Prior FDA agreements waived requirements for comprehensive nonclinical developmental and reproductive toxicity (DART) studies and dedicated oral carcinogenicity studies for EB613.
• EB613 has the potential to be the first oral, once-daily anabolic tablet treatment for osteoporosis, addressing a significant unmet medical need and offering a more convenient alternative to injectable therapies.
• Phase 2 study of EB613 met all biomarker and BMD endpoints without significant safety concerns, with data consistent with published subcutaneous teriparatide at the 6-month time point.

Risks

• Changes in the interpretation of clinical data.
• Results of clinical trials may not be favorable.
• The FDA's interpretation and review of results from and analysis of clinical trials.
• Unexpected changes in ongoing and planned preclinical development and clinical trials.
• Timing of and ability to make regulatory filings and obtain and maintain regulatory approvals for product candidates.
• Potential disruption and delay of manufacturing supply chains.
• Loss of available workforce resources, either by Entera or its collaboration and laboratory partners.
• Impacts to research and development or clinical activities that Entera may be contractually obligated to provide.
• Overall regulatory timelines may be longer than anticipated.
• The size and growth of the potential markets for product candidates may be smaller than expected.
• The scope, progress and costs of developing Entera's product candidates.
• Reliance on third parties to conduct clinical trials.
• Ability to establish and maintain development and commercialization collaborations.
• Operation as a development stage company with limited operating history.
• Competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories.
• Ability to continue as a going concern absent access to sources of liquidity.
• Ability to obtain and maintain regulatory approval for any of its product candidates.
• Ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States.
• Intellectual property position and ability to protect intellectual property.

Future Outlook

Entera Bio plans to advance its clinical development program for EB613, aiming to conduct a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study. The company anticipates EB613 will be the first oral, once-daily anabolic tablet treatment for osteoporosis. The SABRE qualification is still expected this year, which could further validate BMD as a surrogate endpoint. Entera Bio also continues to develop other pipeline candidates, including EB612 for hypoparathyroidism, oral oxyntomodulin for obesity and metabolic syndromes, and oral GLP-2 for rare malabsorption conditions.

Management Comments

• "This regulatory update is a major milestone for Entera and the entire osteoporosis community."
• "Our alignment with the FDA reflects the strength of our data and collaborative discussions. Importantly, it allows us to advance our clinical development program without having to wait for FDAs qualification of the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE), which is still expected this year."
• "We thank the FDA and the Review Team at the Division of Endocrinology for their constructive approach. We also thank the SABRE team for paving the path to innovation for osteoporosis treatment."
• "We are developing EB613 as the first oral, once-daily anabolic tablet treatment to potentially serve this unmet medical need. EB613 is intended to increase skeletal mass, improve bone microarchitecture and reduce the risk of fracture."

Industry Context

Osteoporosis is a widespread and undertreated disease, affecting over 200 million women globally, with one in two women over 50 suffering a fracture. Innovation in osteoporosis treatment has stalled for nearly a decade, with no new drug approved by the FDA since 2019, primarily due to the size, duration, cost, and ethical constraints associated with fracture endpoint studies. Entera Bio's EB613, as a potential first oral, once-daily anabolic tablet, aims to address this significant unmet medical need by offering a more accessible and convenient treatment option compared to existing injectable anabolic therapies.

Comparison to Industry Standards

• The FDA's agreement to use Bone Mineral Density (BMD) as the primary endpoint for EB613's Phase 3 study marks a significant shift from industry precedent, where placebo-controlled Phase 3 studies for new osteoporosis drugs typically required incidence of fracture as the primary endpoint.
• EB613's Phase 2 data, showing rapid dose-proportional increases in bone formation markers and BMD, are consistent with those of published subcutaneous teriparatide at the 6-month time point, suggesting comparable efficacy to existing injectable anabolic therapies.
• Unlike all currently available anabolic therapies for osteoporosis, which are administered by subcutaneous (SC) injection, EB613 is being developed as an oral, once-daily tablet, offering a potentially significant advantage in patient convenience and adherence.
• The SABRE initiative's meta-analysis, including data from 22 randomized, placebo-controlled trials (63,000 participants across seven drug classes), demonstrated that treatment-related gains in total hip BMD explain 72% of observed fracture risk reduction (R2 = 0.73), a correlation double that between blood pressure and stroke (R = 0.37), which is a well-accepted basis for antihypertensive therapy value.

Stakeholder Impact

• Shareholders: Likely positive impact due to de-risked and potentially accelerated clinical development, increased probability of successful market entry for EB613, and enhanced valuation prospects.
• Patients (Post-menopausal women with osteoporosis): Potential for a new, convenient (oral) anabolic treatment option, addressing a significant unmet medical need and potentially improving treatment adherence.
• Healthcare Providers: New and potentially more accessible treatment option for osteoporosis patients, which could improve patient outcomes and management.

Next Steps

• Advance the clinical development program for EB613.
• Initiate and conduct the single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study for EB613.
• Await the FDA's qualification decision for the SABRE initiative, expected this year.
• Present further abstracts at ASBMR and NAMS 2025 conferences.

Key Dates

Recommendation

The FDA's agreement to accept Bone Mineral Density (BMD) as the primary endpoint for the pivotal Phase 3 study of EB613 is a highly significant positive development for Entera Bio. This regulatory flexibility, a departure from the traditional requirement of fracture incidence as a primary endpoint, is expected to substantially reduce the duration, cost, and complexity of the clinical trial. For a clinical-stage biotechnology company, this de-risks the development pathway considerably, potentially accelerating time to market and enhancing the drug's commercial viability. This milestone, combined with prior FDA waivers for DART and carcinogenicity studies, indicates a clear and favorable regulatory path for EB613, positioning Entera Bio strongly in the undertreated osteoporosis market with a potentially first-in-class oral anabolic therapy. This news significantly improves the risk-reward profile of the stock.

Keywords

Entera Bio, EB613, Osteoporosis, FDA, Bone Mineral Density, BMD, Phase 3 Study, Clinical Trial, Oral Peptide, Teriparatide, Anabolic, Post-menopausal, Drug Development, Regulatory Approval, Biotechnology, Pharmaceuticals